New data from AstraZeneca’s coronavirus vaccine trial, which has yet to receive emergency authorization in the United States, is showing positive results.

The latest data from the company published on Monday showed that the vaccine has an efficacy of 79% at preventing symptomatic cases of the coronavirus while being 100% effective at stopping severe disease and hospitalization. The trial included 32,449 participants, and a fifth of them, approximately 8,000 people, were 65 years old or older. 60% of study participants have comorbidities that make them more at risk for a more severe bout with the virus.